•  
  •  
  •  
  •  

2025-11-28 21:34:02

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Cipla Launches India's First Dedicated Lung Health Diagnostics Center in Delhi
  • Ms. Aditi Nayar, Chief Economist at ICRA Ltd On the Fiscal Deficit
  • Authum Investment & Infrastructure Ltd recommends 4:1 bonus issue
  • SBI Capital Markets Report on Q2FY26 GDP - From Capex to Consumption: How Policy Initiatives Sparked a GDP Beat
  • POSTURA: A Wall-Hung Closet Shaped for Comfort, Crafted for Everyday Life

Keywords Selected:  INE750C01026

Stock Report

  • Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
  • Relonchem Limited receives Marketing Authorization for its two products
  • Marksans Pharma Reports Record Q2 FY26 Performance
  • Relonchem Limited receives Marketing Authorization for two of its products
  • Relonchem Limited receives Marketing Authorization for its products
  • Relonchem Limited receives Marketing Authorization for its products
  • Relonchem Limited receives Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution
  • Relonchem Ltd receives Marketing Authorization for the product Gabapentin 50 mg/ml oral solution
  • USFDA inspection at manufacturing facility of Marksans Pharma's subsidiary Time-Cap Laboratories, Inc.
  • Marksans Pharma Ltd's manufacturing facility at Verna, Goa approved by Australian TG
  • Relonchem Limited receives Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA
  • Relonchem Ltd receives Marketing Authorization for Ibuprofen and Paracetamol tablets
  • Relonchem Limited receives Marketing Authorization from UKMHRA for its products
  • UK Relonchem Ltd, receives Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets
  • Relonchem Limited receives UKMHRA Marketing Authorization for its products
  • Relonchem Ltd receives Marketing Authorisation for the product Levetiracetam Relonchem 100 mg/mL Oral Solution
  • Marksans Pharma Limited updates on USFDA inspection at Verna, Goa manufacturing facility
  • Marksans highest ever quarter revenue at Rs 586 crore grew by 22% YoY, and EBITDA at Rs 133 crore grew by 74 % YoY
  • Marksans Pharma Ltd announces US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg
  • Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC)
  • Marksans announces completion of US FDA Post-marketing Adverse Drug Experience inspection
  • Marksans announces FDA approval of OTC equivalent of Advil Dual Action Tablets
  • Marksans Pharma completes the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India
  • Marksans Pharma Ltd announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg

Latest Post

  • Cipla Launches India's First Dedicated Lung Health Diagnostics Center in Delhi
  • Ms. Aditi Nayar, Chief Economist at ICRA Ltd On the Fiscal Deficit
  • Authum Investment & Infrastructure Ltd recommends 4:1 bonus issue
  • SBI Capital Markets Report on Q2FY26 GDP - From Capex to Consumption: How Policy Initiatives Sparked a GDP Beat
  • POSTURA: A Wall-Hung Closet Shaped for Comfort, Crafted for Everyday Life


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024